Pfizer (NYSE:PFE) Given a $50.00 Price Target by Berenberg Bank Analysts

Pfizer (NYSE:PFE – Get Rating) has been assigned a $50.00 target price by Berenberg Bank in a research note issued on Thursday, Borsen Zeitung reports. Berenberg Bank’s price objective suggests a potential upside of 1.81% from the stock’s previous close.

A number of other research firms also recently weighed in on PFE. Sanford C. Bernstein increased their target price on Pfizer from $44.00 to $65.00 and gave the company a “market perform” rating in a report on Monday, January 3rd. BMO Capital Markets increased their target price on Pfizer from $60.00 to $76.00 in a report on Friday, January 14th. StockNews.com raised Pfizer from a “buy” rating to a “strong-buy” rating in a report on Tuesday. The Goldman Sachs Group set a $54.00 target price on Pfizer and gave the company a “neutral” rating in a report on Tuesday, February 8th. Finally, Wells Fargo & Company increased their target price on Pfizer from $60.00 to $65.00 and gave the company an “overweight” rating in a report on Friday, January 7th. Eleven equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $57.80.

Shares of NYSE:PFE traded down $0.64 during midday trading on Thursday, reaching $49.11. 18,851,673 shares of the company’s stock traded hands, compared to its average volume of 32,326,754. The company has a market cap of $277.36 billion, a price-to-earnings ratio of 12.76, a P/E/G ratio of 0.77 and a beta of 0.77. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.19 and a current ratio of 1.40. Pfizer has a one year low of $37.96 and a one year high of $61.71. The stock has a 50 day moving average of $50.87 and a 200 day moving average of $51.07.

Pfizer (NYSE:PFE – Get Rating) last announced its quarterly earnings results on Tuesday, February 8th. The biopharmaceutical company reported $1.08 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.85 by $0.23. The firm had revenue of $23.84 billion for the quarter, compared to the consensus estimate of $24.20 billion. Pfizer had a return on equity of 34.53% and a net margin of 26.97%. The company’s quarterly revenue was up 104.0% on a year-over-year basis. During the same period in the prior year, the company posted $0.42 earnings per share. Sell-side analysts predict that Pfizer will post 7.28 EPS for the current fiscal year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Bank OZK increased its position in shares of Pfizer by 0.3% during the 4th quarter. Bank OZK now owns 68,883 shares of the biopharmaceutical company’s stock valued at $4,067,000 after purchasing an additional 195 shares during the last quarter. TimeScale Financial Inc. increased its position in shares of Pfizer by 2.9% during the 4th quarter. TimeScale Financial Inc. now owns 6,978 shares of the biopharmaceutical company’s stock valued at $412,000 after purchasing an additional 196 shares during the last quarter. Bath Savings Trust Co increased its position in shares of Pfizer by 0.5% during the 4th quarter. Bath Savings Trust Co now owns 39,684 shares of the biopharmaceutical company’s stock valued at $2,344,000 after purchasing an additional 200 shares during the last quarter. Fruth Investment Management increased its position in shares of Pfizer by 0.7% during the 4th quarter. Fruth Investment Management now owns 29,313 shares of the biopharmaceutical company’s stock valued at $1,730,000 after purchasing an additional 200 shares during the last quarter. Finally, Winfield Associates Inc. increased its position in shares of Pfizer by 0.9% during the 4th quarter. Winfield Associates Inc. now owns 21,557 shares of the biopharmaceutical company’s stock valued at $1,273,000 after purchasing an additional 200 shares during the last quarter. 64.96% of the stock is currently owned by hedge funds and other institutional investors.

Pfizer Company Profile (Get Rating)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.

Featured Articles